Clinical Trials Sponsored by AztraZeneca

Total 4284 results

AstraZeneca

Completed

A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone (IMPRESS)

Non-Small Cell Lung Cancer

Italy, Spain, France, Korea, Republic of, Hungary, Japan, China, Taiwan, Hong Kong, Germany, Russian Federation
AstraZeneca

Completed

A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia (HARMONIZE GL)

Hyperkalemia

Korea, Republic of, Taiwan, Russian Federation, Japan
AstraZeneca

Completed

Specific Clinical Experience Investigation for Long-term Use of Bydureon.

Type 2 Diabetes

Japan
AstraZeneca

Completed

Prevalence of Asthma and Allergies Among Children in UAE (ISAAC-UAE)

Asthma

United Arab Emirates
AstraZeneca

Completed

Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region (PREDICT)

Ovarian Cancer

United Arab Emirates
AstraZeneca

Completed

FLABRA: Frontline Approach for BRCA Testing in OC Treatment naïve Population. A LATIN AMERICA Epidemiologic Study (FLABRA)

Ovarian Cancer

Brazil, Panama, Colombia, Argentina, Mexico, Peru
AstraZeneca

Approved for marketing

An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia (MOXE)

Relapsed/Refractory Hairy Cell Leukemia
AstraZeneca

Completed

A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Diabetes

United States, United Kingdom, Germany, Hungary, Mexico, Poland, Russian Federation, Romania, Czechia, Sweden
AstraZeneca

Completed

Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer). (CONCORDANCE)

NSCLC (Non-small Cell Lung Cancer)

India
AstraZeneca

Completed

"Me and My Heart" Study (eMocial)

Acute Coronary Syndrome

Germany
AstraZeneca

Completed

AZD8186 First Time In Patient Ascending Dose Study

Advanced Castrate-resistant Prostate Cancer CRPC | Squamous Non-Small Cell Lung Cancer sqNSCLC | Triple Negative Breast Cancer TNBC

Spain, Canada, United States, United Kingdom
AstraZeneca

Completed

Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia

Hyperkalemia

Japan
AstraZeneca

Terminated

Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium

Heart Failure

Czechia, Bulgaria, Poland, United Kingdom
AstraZeneca

Completed

Type 2 Diabetes Mellitus Patients' Characteristics and Management by General Practitioners and Endocrinologists

Type 2 Diabetes Mellitus

Russian Federation
AstraZeneca

Completed

307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric Subjects

Hypertension

United States, Dominican Republic
AstraZeneca

Completed

Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria

Type 2 Diabetes | Albuminuria | Hyperuricemia

United States
AstraZeneca

Completed

A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg (FINDER II)

Advanced Breast Cancer | Metastatic Breast Cancer

Belgium, Turkey, Canada, Poland, Romania, Hungary, France, Czechia
AstraZeneca

Completed

Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes

Type 2 Diabetes

Japan
AstraZeneca

Completed

Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer (ICEBERG 3)

Ovarian Neoplasms

Spain, United States, Belgium, United Kingdom, Israel, Poland, Germany, Sweden, Australia
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Melanoma | Breast Cancer | Colorectal Cancer | Pancreatic Adenocarcinoma | Lung Cancer | Head and Neck Carcinoma | Biliary Tract Cancer | Gastroesophageal Cancer

United States
AstraZeneca

Completed

To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer

Solid Tumours

Belgium, Denmark, France, United Kingdom, Netherlands
AstraZeneca

Completed

Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment

Solid Tumours

France, United Kingdom, Czechia, Korea, Republic of, Netherlands
AstraZeneca

Completed

Pharmacokinetic Study of Benralizumab in Healthy Chinese Subjects

Healthy Subjects

Hong Kong
AstraZeneca

Completed

Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma

Metastatic Pancreatic Ductal Adenocarcinoma

United States, United Kingdom
AstraZeneca

Completed

Nexium Capsules Non-steroidal Anti-inflammatory Drug (NSAID) Specific Clinical Experience Investigation

Gastric Ulcer | Duodenal Ulcer

Japan
AstraZeneca

Completed

Nexium Capsules LDA Specific Clinical Experience Investigation

Gastric Ulcer | Duodenal Ulcer

Japan
AstraZeneca

Completed

The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.

Advanced Solid Tumours

China
AstraZeneca

Completed

A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients

Advanced Solid Malignancies

Japan
AstraZeneca

Completed

A 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With T2DM

Type 2 Diabetes Mellitus

United States
AstraZeneca

Completed

A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers

Heart Failure With Preserved Ejection Fraction (HFpEF)

United States
AstraZeneca

Completed

Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours

Advanced Solid Tumours

Korea, Republic of, Australia, Japan
AstraZeneca

Terminated

Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours

Cancer | Advanced Solid Malignancies

United States, Italy, United Kingdom, France, Germany, Spain, Netherlands
AstraZeneca

Completed

Rosuvastatin Adherence App Study in China (eHELP China)

Dyslipidemia | Hyperlipidemia

China
AstraZeneca

Completed

Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

Diabetes Mellitus

United States, Hungary, South Africa, Slovakia, Romania, Poland
AstraZeneca

Completed

Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer

Breast Cancer

Thailand, Korea, Republic of, Japan, Philippines, Taiwan, India
AstraZeneca

Completed

Single + Multiple Ascending Dose and Food Effect Study of AZD7986 in Healthy Volunteers, PK, PD and Safety Study

Safety, Pharmacokinetics, Pharmacodynamics, Food Effect

United Kingdom
AstraZeneca

Completed

Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

T790M Positive NSCLC Patients

China
AstraZeneca

Completed

AMPLIFY - D6571C00001 Duaklir USA Phase III Study

Chronic Obstructive Pulmonary Disease

United States, Germany, Poland, Israel, Bulgaria, Czechia, Hungary, Spain, Ukraine, United Kingdom
AstraZeneca

Completed

A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567.

Rheumatoid Arthritis | Healthy Subjects | Pharmacokinetics | Pharmacodynamics | Tolerability | Safety

Germany
AstraZeneca

Completed

AZD0585 Phase III Long-term Study in Japan

Hypertriglyceridemia

Japan
AstraZeneca

Completed

A Real-World Assessment of a COPD Disease Management Support Service (Me & My COPD) (Me&MyCOPD)

Chronic Obstructive Pulmonary Disease

United Kingdom
AstraZeneca

Completed

Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis] (BATT)

Puberty, Precocious

United States, Canada, Russian Federation, France, India, United Kingdom
AstraZeneca

Completed

Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home

Asthma

United States, Canada
AstraZeneca

Completed

A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma (STRATOS2)

Uncontrolled Asthma

United States, Canada, Italy, United Kingdom, Philippines, Japan, Russian Federation, South Africa, Taiwan, Czechia, Mexico, Ukraine, Chile
AstraZeneca

Completed

Single Dose Study to Assess Efficacy, Safety and Tolerability of LAS100977 in Asthmatic Patients.

Asthma

Germany, United Kingdom
AstraZeneca

Completed

Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer

Belgium, Canada, Austria, Australia
AstraZeneca

Completed

A Study to Evaluate the Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia

Homozygous Familial Hypercholesterolemia (HoFH)

Malaysia, Canada, Taiwan, Belgium, Denmark, Israel
AstraZeneca

Completed

Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects

Kidney Failure, Chronic

United States
AstraZeneca

Completed

Observational Multicenter Non-interventional Study on COPD Patients Treatment Strategies at the Time of Hospital Discharge and Within 12 Months of Follow-up on an Outpatient Primary Care Basement (CLOUD)

COPD

Russian Federation
AstraZeneca

Completed

A Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS)

Hyperkalemia

Hong Kong

3

Subscribe